Key result
Magnesium bioresorbable stents yield a 9% target lesion failure rate, occurring exclusively in ACS patients.
Why the study?
A magnesium-based sirolimus-eluting bioresorbable stent recently gained CE-mark after promising results in the BIOSOLVE studies, prompting evaluation of clinical outcomes in hospital practice.
Observational (n=38)
No
Answers are grounded in this paper and cite their sources.
Signals higher TLF risk in ACS; leaves open magnesium stent role in stable disease pending larger trials.
A bioresorbable stent (MgBVS) made from a magnesium backbone coated by a biodegradable polymer eluting sirolimus recently gained CE-mark after the promising results of the BIOSOLVE studies. We present 6-mo clinical outcome of consecutive patients treated in our hospital with at least one MgBVS.
No takes yet. Share an insight, caveat, or question.
Carlier et al. (2020) conducted an observational in Chronic and acute coronary syndromes (n=38). Magnesium-based bioresorbable stent (MgBVS) was evaluated on Target lesion failure (TLF) at 6 months. Implantation of a magnesium-based bioresorbable stent resulted in a 9% overall rate of target lesion failure at 6 months, with all events occurring in patients with acute coronary syndrome.
Synapse has enriched 10 related papers. Consider them for comparative context: